Cervical cancer and HPV vaccines in developing countries

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 6, 2009, Pages 969-974

  Zarchi, Mojgan Karimi ^a   Behtash, Nadereh ^b   Chiti, Zohreh ^a   Kargar, Saeed ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cervical cancer; Hpv; Prevention; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; CHILD; DEVELOPING COUNTRY; FEMALE; HUMAN; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; CHILD; DEVELOPING COUNTRIES; FEMALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77956628001     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (47)

1. American College of Obstetricians and Gynecologists (2003). ACOG practice Bulletin 45: Cervical Cytology Screening. Obstet Gynecol, 102, 417-27.
2. Announcement the Society of Gynecologic Oncologists (2006). Statement on a Cervix Cancer Vaccine. Gynecol Oncol, 101, 377.
3. Behbakht K, Lynch A, Teal S, et al (2004). Social and cultural barriers to Papanicolaou test screening in an urban population Obstet Gynecol, 104, 1355-61.
4. Behtash N, Ghaemmaghami F, Ayatollahi H, et al (2005). A case control study to evaluate urinary tract complications in radical hysterectomy. World J Surg Oncol, 3, 12.
5. Behtash N, Mousavi A, Mohit M, et al (2003). Simple hysterectomy in the presence of invasive cervical cancer in Iran. Int J Gynecol Cancer, 13, 177-81.
6. Behtash N, Nazari Z, Ayatollahi H, et al (2006). Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage 11b-11A cervical cancer. Eur J Surg Oncol, 32,1226-30.
7. Belinson J, Quo YL, Pretorius R, et al (2001). Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gyncecol Oncol, 83, 439-44.
8. Bernstein SJ, Sanchez-Ramos L, Ndubisi B (2001). Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a meta-analysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol, 185, 308-17.
9. Blumenthal PD, Gaffikin L, Chirenje ZM, et al (2001). Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet, 72, 47-53.
10. Bundrick JB, Cook DA, Gostout BS (2005). Screening for cervical cancer and initial treatment of patients with abnomal results from papanicolaou testing. Mayo Clin Proc, 80, 1063-8.
11. Castellsague X, Diaz M, De Sanjose S, et al (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst, 98, 303-15.
12. Castle PE, Solomon D, Schiffman M, et al (2005). Human papilloma virus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst, 97, 1066-71.
13. Clavel C, Masure M, Bory JP, et al (1999). Hybrid capture 11-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer, 80, 1306-11.
14. Clavel C, Masure M, Bory JP, et al (2001). Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer, 84, 1616-23.
15. Cooper CP, Saraiya M, McLean TA, et al (2005). Report from the CDC. Pap test intervals used by physicians serving lowincome women through the national breast and cervical cancer early detection program. J Womens Health, 14, 670-8.
16. Cuzick J, Szarewski A, Cubic H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362, 1871-6.
17. Cuzick J, Beverley E, Ho L, et al (1999). HPV testing in primary screening of older women. Br J cancer, 81, 554-558.
18. Daling JR, Madeleine MM, Johnson LG, et al (2004). Human papilloma virus, smoking, and sexual practices in the etiology of anal cancer. Cancer, 101, 270-80.
19. Einstein MH, Cruz Y, El-Awady MK, et al (2002). Utilization of the human genoume sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year old woman. Clin Cancer Res, 8, 549-554.
20. Franco EL (2003). Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr, 31, 89-96.
21. Freeman HP, Wingrove BK (2005). Excess cervical cancer mortality: a marker for low access to health care in poor communities. In: institute NC, editor. Rockville, MD: Center to Reduce cancer Health Disparities,345-400.
22. Frisch M, Biggar RJ, Goedert JJ (2000). Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst, 92, 1500-10.
23. Ghaemmaghami F, Karimi Zarchi M, Mousavi A et al (2008). Results of cervical cone excision biopsy in Iran. Asian Pac J Cancer Prev, 9, 45-7.
24. Harper DM, Franco EL, Wheeler CM, et al (2006). Sustained efficacy up to 4-5 years of a bivalent Ll virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up form a randomized control trial. Lancet, 367, 1247-55.
25. Hoyo C, Yarnall KS, Skinner CS, et al (2005). Pain predicts non-adherence to pap smear screening among middle-aged African American women. Prev Med, 41, 439-45.
26. Jacobs EA, Karavolos K, Rathouz PJ, et al (2005). Limited English proficiency and breast and cervical cancer screening in a multiethnic population. Am J Public Health, 95, 1410-6.
27. Jacobs MV, Walboomers JM, Snijders PJ, et al (2000). Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer, 87, 221-7.
28. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics 2006; CA Cancer J Clin, 56, 1006-30.
29. Khan MJ, Castle PE, Lorincz AT, et al (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type specific HPV testing in clinical practice. J Natl Cancer Inst, 97, 1072-9.
30. Kjaer SK, Van Den Brule AJC, Paull G, et al (2002). Type of persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ, 325, 572-6.
31. Kulasingam SL, Hughes JP, Kiviat NB, et al (2002). Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 288, 1749-57.
32. Kyndi M, Frederiksen K, Kruger-Kjaer S (2006). Cervical cancer incidence in Denmark over six decades (1994-2000). Acta Obstet Gynecol Scand, 85, 106-111.
33. Marino JF, Fremont-Smith M (2001). Direct-to-vial experience with autoCyte PREP in a small New England cytology practice. J Reprod Med, 46, 353-8.
34. Mao C, Koutsky LA, Ault KA, et al (2006). Efficacy of human papillomaviurs-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol, 107, 18-27
35. Munoz N, Bosch FX, De Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
36. Mousavi A, Karimi Zarchi M, Gilani MM, et al (2008). Radical hysterectomy in the elderly. World J Surg Oncol, 6, 38.
37. Mousavi A, Karimi Zarchi M (2007). Isolated cervical metastasis of breast cancer: a case report and literature review. J Low Genit Tract Dis, 11, 276-8.
38. Nanda K, McCrory DC, Myers ER, et al (2000). Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med, 132, 810-9.
39. Obwegeser JH, Brack S (2001). Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases. Acta Cytol, 45, 709-14.
40. Saslow D, Runowicz CD, Solomon D, et al (2002). American Cancer society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin, 52, 342-62.
41. Schiffman M, Kjaer SK (2003). Natural history of anogenital human papilloma virus infection and neoplasia. J Natl Cancer Inst Monogr, 31, 14-9.
42. Schneider A, Hoyer H, Lotz B, et al (2000). Screening for highgrade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer, 89, 529-534.
43. Sherman ME, Lorincz AT, Scott DR, et al (2003). Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year Cohort analysis. J Natl Cancer Inst, 95, 46-52.
44. Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (type 6, 11, 16 and 18) Ll virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
45. Wang SS, Sherman ME, Hildesheim A et al (2004). Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer, 100, 1035-44.
46. Wright Jr TC, Schiffman M (2003). Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med, 348, 489-90.
47. Wright TC, Schiffman M, Solomon D, et al (2004). Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol, 103, 304-9.